Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.

ESMO Open · 2016 · PMC5566979 · PMID 28861280

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although the ORR in these patients did not reach statistical significance (OR 0.13; 95% CI 0.02 to 1.07), it was higher in EGFR mutation wild type/unknown than positive patients (28.6% (n=16/56) vs 5.0% (n=1/20); table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.